Long-term results of a low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukemia and myelodysplastic syndrome in children with Down syndrome
Bibliographic record
Abstract
4325 Children with Down syndrome (DS) have an estimated 500-fold increased risk of acute megakaryoblastic leukemia (DS-AMKL), which is frequently preceded by a myelodysplastic syndrome. The leukemic blasts of DS-AMKL uniquely harbor somatic mutations of the hematopoietic transcription factor GATA1 and are highly sensitive to cytarabine in vitro . Highly dose-intensive chemotherapy regimens developed for the general pediatric population result in excessive treatment-related mortality in children with DS. Thus, a low dose chemotherapy approach has been developed, in which cytarabine (10 mg/m2/dose) is administered subcutaneously to out-patients over a prolonged period of time. We report the outcomes of 18 children with DS and AMKL (or MDS) treated with a low dose regimen and 16 patients treated with standard dose chemotherapy at The Hospital for Sick Children and collaborating centers between 1990 and 2003. In the low dose group, 15 of 18 patients (83.3 %) achieved a complete remission. Of three patients with refractory leukemia, one achieved a long term remission after subsequent treatment with standard therapy. Twelve of the 15 responders remain in continuous remission (median duration 93 months; range 4 to156 months). All five deaths (27%) in the low dose group were due to refractory or relapsed disease (in three cases no second chemotherapy regimen was used). In the standard dose group, 15 of 16 patients (93.7%) achieved a complete remission lasting for a median duration of 57 months (range 5 to 152 months). One patient, who showed no response, was subsequently treated with intensive AML chemotherapy (UKMRCAML 10) and remains in remission. Three of the 15 responding patients relapsed: one patient received a stem cell transplant and died in remission from pulmonary hypertension; two patients were refractory to further therapy and died. In a intention-to-treat analysis, the event-free and overall survival were not significantly different in the low dose and standard dose group (EFS 66.7 and 75.0%, p=0.5; OS 76.5% and 80.4 %, p=0.6, respectively). In the entire cohort age, gender and cytogenetic abnormalities in addition to constitutional trisomy 21 were not associated with significant differences in survival. Two patients with monosomy 7 in the low dose group died compared to a EFS of 66.7% of 3 patients with monosomy 7 in the standard dose group. Based on the largest experience reported to date on the use of low-dose cytarabine for the treatment of AMKL in children with DS, we conclude that this therapeutic option merits prospective evaluation.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".